Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Varga

Showing results (441-450 of 445) with videos related to

Pageof 45
Sort By:
You have reached the last page of results.This site can display upto 445 results.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
BMC Genomics|November 1, 2015
Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strainsJohn J Varga, Mariette Barbier, Xavier Mulet, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 45

Showing results (441-450 of 445) with videos related to

Sort By:
Pageof 45
You have reached the last page of results.This site can display upto 445 results.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
BMC Genomics|November 1, 2015
Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strainsJohn J Varga, Mariette Barbier, Xavier Mulet, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Pageof 45